Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Ulipristal acetate (Esmya®) is recommended as an option for use within NHS Wales for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed. |
|||
|
|||
Medicine details |
|||
| Medicine name | ulipristal acetate (Esmya®) | ||
| Formulation | 5 mg tablet | ||
| Reference number | 2767 | ||
| Indication | Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed |
||
| Company | Gedeon Richter UK Ltd | ||
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 0716 | ||
| NMG meeting date | 10/02/2016 | ||
| AWMSG meeting date | 23/03/2016 | ||
| Ratification by Welsh Government | 05/04/2016 | ||
| Date of issue | 12/04/2016 | ||
| Date of last review | February 2021 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation on ulipristal acetate for the pre-operative treatment of moderate to severe symptoms of uterine fibroids (Advice number 1913, originally published July 2013). This advice has been updated to align with the restriction made to the licence indication by the European Medicines Agency in February 2021. |
|||